


Synthesis of 2-(Substituted Phenyl)-3,5,5-trimethylmorpholine Analogues and Their Effects on Monoamine Uptake, Nicotinic Acetylcholine Receptor Function, and Behavioral Effects of Nicotine

F. Ivy Carroll,^{*,†} Ana Z. Muresan,[†] Bruce E. Blough,[†] Hernán A. Navarro,[†] S. Wayne Mascarella,[†] J. Brek Eaton,[§] Xiaodong Huang,[†] M. Imad Damaj,[‡] and Ronald J. Lukas[§][†]Center for Organic and Medicinal Chemistry, Research Triangle Institute, P. O. Box 12194, Research Triangle Park, North Carolina 27709-2194, United States[‡]Department of Pharmacology and Toxicology, Virginia Commonwealth University Medical Center, Richmond, Virginia 23298-0613, United States[§]Division of Neurobiology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, Arizona 85013, United States

S Supporting Information

ABSTRACT: Toward development of smoking cessation aids superior to bupropion (**2**), we describe synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues **5a–5h** and their effects on inhibition of dopamine, norepinephrine, and serotonin uptake, nicotinic acetylcholine receptor (nAChR) function, acute actions of nicotine, and nicotine-conditioned place preference (CPP). Several analogues encompassing aryl substitutions, *N*-alkylation, and alkyl extensions of the morpholine ring 3-methyl group provided analogues more potent in vitro than (*S,S*)-hydroxybupropion (**4a**) as inhibitors of dopamine or norepinephrine uptake and antagonists of nAChR function. All of the new (*S,S*)-**5** analogues had better potency than (*S,S*)-**4a** as blockers of acute nicotine analgesia in the tail-flick test. Two analogues with highest potency at $\alpha 3\beta 4^*$ -nAChR and among the most potent transporter inhibitors have better potency than (*S,S*)-**4a** in blocking nicotine-CPP. Collectively, these findings illuminate mechanisms of action of **2** analogues and identify deshydroxybupropion analogues **5a–5h** as possibly superior candidates as aids to smoking cessation.



■ INTRODUCTION

Tobacco product use, principally via cigarette smoking, is the number one cause of premature death in the United States (Centers for Disease Control and Prevention, 2002). There are more than 440000 deaths due to cigarette smoking, and more than \$75 billion in annual medical costs is attributed to smoking (NIDA, 2006; Centers for Disease Control and Prevention, 2008; Centers for Disease Control and Prevention, 2005). It is now commonly accepted that smoking behavior is maintained to a large extent by the reinforcing effects of nicotine (**1**) and aversive effects of nicotine withdrawal.^{1–4} Both nonpharmacological and pharmacological interventions have demonstrated efficacy in smoking cessation.⁵ At present, first-line pharmaceutical treatments include nicotine replacement therapy or use of bupropion (**2**) or varenicline (**3**).^{6,7} While these treatments are useful in helping about 20% of smokers abstain long-term, new pharmacotherapies are needed that are either more effective or can impact those individuals not helped by existing treatments.

While nicotine replacement therapy and **3** act on nicotinic receptors as their primary targets, **2** seems to engage additional targets. We have hypothesized that **2**, or more specifically its active (*S,S*)-hydroxymetabolite (*S,S*)-**4a** (see Carroll et al., 2010)⁸ fits the multiple molecular target model of drug action. This model postulates that the combination of effects of **2** or active metabolites on dopamine (DA) transporter (DAT),


norepinephrine (NE) transporter (NET), and nicotinic acetylcholine receptor (nAChR) function is important to its therapeutic efficacy as a smoking cessation agent.^{9,10} The model also suggests that fine-tuning of effects on DA and NE availability and on nAChR function could lead to superior aids to smoking cessation. We have chosen **2** as a template for such work.

Our earlier work toward a goal of developing superior aids to smoking cessation concerned analogues of **2**, its (*S,S*)- or (*R,R*)-hydroxymetabolites (*S,S*)-**4a** or (*R,R*)-**4a**, respectively, or 3-phenyltropane-related compounds.^{8,11–13} Several of these agents have superior activities relative to **2** or its active metabolite (*S,S*)-**4a** as inhibitors of DA or NE uptake or of nAChR function and have very promising In Vivo profiles as inhibitors of nicotine-induced dependence behaviors.^{8,11–13}

To explore potential utility as smoking cessation aids of compounds having related structural topology and to define possible mechanism(s) of action of these compounds, we now describe the synthesis and in vitro and In Vivo effects of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues **5a–5h**. Compounds (*S,S*)- and (*R,R*)-**5a** are analogues of the hydroxybupropion metabolites (*S,S*)- and (*R,R*)-**4a**, where the hydroxy group has been replaced by a hydrogen. We also synthesized and studied analogues (*S,S*)-**5b–5h**. In this study,


Received: November 11, 2010

Published: February 14, 2011

Scheme 1^a

^a Reagents: (a) NaBH₄, CH₃OH; (b) CH₂Cl₂, H₂SO₄; (c) MeI, DMF, 70 °C for **5d**; (d) Na(OAc)₃BH, acetaldehyde for **5e** or propionaldehyde for **5f**.

we report the identification of ligands with superior in vitro and preliminary In Vivo activity profiles than those for (*S,S*)-**4a**.



CHEMISTRY

Analogues **5a–5c**, **5g**, and **5h** were synthesized in a fashion similar to that reported in the literature for optically active phenmetrazine (Scheme 1).¹⁴ The keto forms of the previously reported hydroxymorpholines **4a–4c**, **4g**, and **4h** were reduced with sodium borohydride to afford mixtures of diastereomeric diols **6a–6c**, **6g**, and **6h**, varying at the benzylic hydroxyl position. The morpholine ring structure could then be formed by cyclization using sulfuric acid in methylene chloride to form the optically active phenylmorpholines **5a–5c**, **5g**, and **5h**. The diastereomeric benzyl alcohol is presumably removed forming a benzylic cation, which is then trapped by the primary alcohol. Cyclization afforded the thermodynamically and kinetically more stable trans isomer. The optical activity is thus controlled by the methyl group alpha to the nitrogen. *N*-Methylation of (*S,S*)-**5a** to form **5d** was done using methyl iodide in dimethylformamide at 70 °C. *N*-Alkylation of (*S,S*)-**5a** to form **5e** and **5f** was accomplished by standard reductive alkylation using acetaldehyde and propionaldehyde, respectively, and sodium triacetoxyborohydride in methylene chloride.

Analogue Characterization in Vitro. Compound (*S,S*)-**4a** has IC₅₀ values of 630 and 180 nM for DA and NE uptake inhibition and is inactive for 5HT uptake inhibition (Table 1). The (*R,R*)-isomer (*R,R*)-**4a** is inactive as a DA and 5HT uptake inhibitor with much lower potency for NE uptake inhibition

(IC₅₀ = 9900 nM) than (*S,S*)-**4a**. Compound (*S,S*)-**5a**, with IC₅₀ values of 220, 100, and 390 nM for DA, NE, and 5HT uptake inhibition, respectively, is a more potent inhibitor of uptake of all three neurotransmitters than (*S,S*)-**4a**. The (*R,R*)-**5a** isomer is less potent at all three transporters than (*S,S*)-**5a**, as was seen for the pair of hydroxyl analogues, but was more potent than (*R,R*)-**4a** for DA and NE uptake inhibition.

Replacement of the chloro group in (*S,S*)-**5a** with a fluoro group to give (*S,S*)-**5b** results in a 3.7- and 3.2-fold increase in the potency for inhibition of DA and NE uptake but a 12-fold decrease in potency for inhibition of 5HT uptake (Table 1). Compared to (*S,S*)-**4a**, **5b** is 10- and 5.6-fold more potent as a DA and NE uptake inhibitor. The arylbromo analogue **5c**, with an IC₅₀ value of 44 nM for inhibition of DA uptake, is 5-fold more potent than **5a** at DAT but has essentially the same potency as **5a** for inhibition of NE and 5HT uptake.

The addition of an *N*-methyl group to (*S,S*)-**5a** to give **5d** had little effect on monoamine uptake inhibition potency (Table 1). In contrast, the addition of an *N*-ethyl or *N*-propyl group to **5a** to give **5e** and **5f**, respectively, resulted in a 4- to 7.8-fold increase in potency (relative to (*S,S*)-**5a**) for DA and NE uptake inhibition and a 4- to 7-fold decrease in 5HT uptake inhibition potency.

Compounds **5g** and **5h**, which have 3-ethyl and 3-propyl groups in place of the 3-methyl group in (*S,S*)-**5a**, have IC₅₀ values of 23 and 6.0 nM for DA uptake inhibition, 19 and 9 nM for NE uptake inhibition, and 1800 and 300 nM for 5HT uptake inhibition (Table 1). Thus, they are the most potent of the analogues tested as DA uptake inhibitors and share with the *N*-ethyl and *N*-propyl analogues highest potency as NE uptake inhibitors.

The effects of 3,5,5-trimethylmorpholine analogues (*S,S*)- and (*R,R*)-**4a**, (*S,S*)- and (*R,R*)-**5a**, and **5b–5h** on function of diverse human nAChR subtypes naturally or heterologously expressed by human cell lines were assessed using ⁸⁶Rb⁺ efflux assays that are specific only for nAChR function in the cells used. None of the analogues has activity as agonists at α1*, α3β4*, α4β2-, or α4β4-nAChR because ⁸⁶Rb⁺ efflux in the presence of these ligands alone at concentrations from ~5 nM to 100 μM (data not shown here) was indistinguishable from responses in cells exposed only to efflux buffer. ⁸⁶Rb⁺ efflux assays also were used

Table 1. Analogue Inhibition of Monoamine Uptake and Nicotinic Acetylcholine Receptor (nAChR) Function

5

compd	R ₁	R ₂	X	monoamine uptake inhibition ^a IC ₅₀ (nM)			nAChR inhibition ^b IC ₅₀ (μM)			
				[³ H]DA	[³ H]NE	[³ H]SHT	α3β4*–	α4β2–	α4β4–	α1*–
2 ^c				660 ± 180	1900 ± 300	IA	1.8 (1.15)	12 (1.15)	15 (1.07)	7.9 (1.12)
(<i>S,S</i>)-4a ^c				630 ± 50	180 ± 4	IA	11 (1.48)	3.3 (1.07)	30 (1.10)	28 (1.45)
(<i>R,R</i>)-4a ^c				IA	9900 ± 1400	IA	6.5 (1.20)	31 (1.12)	41 (1.07)	7.5 (1.10)
(<i>S,S</i>)-5a	CH ₃	H	Cl	220 ± 60	100 ± 30	387 ± 140	3.3 ±	20 (0.06)	30 (1.12)	NT
(<i>R,R</i>)-5a	CH ₃	H	Cl	1600 ± 270	1200 ± 300	IA	1.6 (1.07)	17 (1.06)	12 (1.06)	9.4 (1.05)
(<i>S,S</i>)-5b	CH ₃	H	F	61 ± 20	32 ± 3	4600 ± 430	5.6 (1.04)	23 (1.05)	55 (1.10)	34 (1.07)
(<i>S,S</i>)-5c	CH ₃	H	Br	44 ± 3	150 ± 20	390 ± 30	1.4 (1.12)	12 (1.06)	11 (1.07)	7.3 (1.07)
(<i>S,S</i>)-5d	CH ₃	CH ₃	Cl	230 ± 60	170 ± 20	540 ± 130	2.8 (1.09)	16 (1.14)	23 (1.09)	21 (1.05)
(<i>S,S</i>)-5e	CH ₃	C ₂ H ₅	Cl	44 ± 9	24 ± 8	1500 ± 300	0.79 (1.06)	7.2 (1.06)	6.4 (1.04)	14 (1.05)
(<i>S,S</i>)-5f	CH ₃	C ₃ H ₇	Cl	61 ± 20	13 ± 3.6	2900 ± 400	0.98 (1.06)	12 (1.06)	5.8 (1.04)	5.5 (1.06)
(<i>S,S</i>)-5g	C ₂ H ₅	H	Cl	23 ± 5	19 ± 3	1800 ± 30	5.6 (1.16)	14 (1.05)	15 (1.10)	13 (1.07)
(<i>S,S</i>)-5h	C ₃ H ₇	H	Cl	6.0 ± 1	9 ± 2	300 ± 100	3.1 (1.15)	9.5 (1.04)	8.0 (1.12)	5.0 (1.08)

^a Values for mean ± standard error of three independent experiments, each conducted with triplicate determination. ^b Mean micromolar IC₅₀ values (to two significant digits) for (*S,S*)- and (*R,R*)-hydroxybupropions (4a and 4b) and the indicated 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues from three independent experiments for inhibition of functional responses to an EC₈₀–EC₉₀ concentration of carbamylcholine mediated by nAChR subtypes composed of the indicated subunits (where * indicates that additional subunits are or may be additional assembly partners with the subunits specified; see Experimental Section). Numbers in parentheses indicate SEM as a multiplication/division factor of the mean micromolar IC₅₀ values shown (i.e., the value 1.8 (1.15) reflects a mean IC₅₀ value of 1.8 μM with an SEM range of 1.8 × 1.15 μM to 1.8/1.15 μM or 1.6–2.1 μM). IA: IC₅₀ > 100 μM. NT: not determined. ^c Taken from ref 13.

to assess whether ligands had activity as antagonists at human nAChR. Representative concentration–response curves for selected ligands illustrate their nAChR in vitro inhibitory profiles (Figure 1; see also Table 1). Other studies (not shown here) indicate that each of the ligands acts via noncompetitive inhibition of nAChR function.

Compound (*S,S*)-4a has IC₅₀ values of 11, 3.3, 30, and 28 μM for functional antagonism of α3β4*, α4β2-, α4β4-, and α1β1*-nAChRs, respectively, meaning that it has 3–10-fold selectivity for α4β2-nAChR over other subtypes. Its potency as a functional antagonist of α4β2-nAChR, which are strongly implicated in nicotine dependence, is ~10-fold higher than that of (*R,R*)-4a, which is slightly more potent than (*S,S*)-4a as an antagonist of α3β4*- and α1*-nAChR. The (*S,S*)-deshydroxy analogue, (*S,S*)-5a, with IC₅₀ values of 3.3 μM at α3β4*-nAChR and 20 μM at α4β2-nAChR, is three times more potent at α3β4*-nAChR and seven times less potent at α4β2-nAChR than (*S,S*)-4a. Importantly, (*S,S*)-5a has selectivity for α3β4*-nAChR over α4β2-nAChR as does (*R,R*)-4a but opposite to the α4β2-nAChR selectivity of the sister isomer, (*S,S*)-4a. Both (*S,S*)-4a and (*S,S*)-5a have lower potencies at α4β4- and α1β1*-nAChR than at α3β4*- or α4β2-nAChR. Interestingly, (*R,R*)-5a has an IC₅₀ value of 1.6 μM at α3β4*-nAChR, making it the most potent at this nAChR subtype of the 4a or 5a ligands, and is 11-, 7.4-, or 5.8-fold more selective for α3β4*-nAChR relative to α4β2-, α4β4-, or α1*-nAChR subtypes. It is also 6.5- and 4-times more potent as an α3β4*-nAChR antagonist than (*S,S*)- and (*R,R*)-4a.

Aryl halogen substitution of the chloro group in (*S,S*)-5a to a fluoro group to give (*S,S*)-5b slightly decreased, whereas change to a bromo group in 5c produced an ~2-fold increase in antagonist potency at α3β4*-nAChR but also had similar effects




Figure 1. Specific ⁸⁶Rb⁺ efflux (ordinate; percentage of control) was determined for functional, human muscle-type α1β1γδ-nAChR (■), ganglionic α3β4*-nAChR (○), α4β2-nAChR (▲), or α4β4-nAChR (▽) naturally or heterologously expressed in human cell lines in the presence of a receptor subtype-specific, EC₈₀–EC₉₀ concentration of the full agonist, carbamylcholine, either alone or in the presence of the indicated concentrations (abscissa, log molar) of (*S,S*)-5a, (*R,R*)-5a, 5e, or 5f as indicated. Mean micromolar IC₅₀ values and SEM as a multiplication/division factor of the mean micromolar IC₅₀ value are provided in Table 1.

on the other nAChR subtypes tested, thus not markedly altering nAChR selectivity.

Table 2. Pharmacological Evaluation of 3,5,5-Trimethylmorpholine Analogues as Noncompetitive Nicotinic Antagonists^{a, b}

compd	AD ₅₀ (mg/kg)				
	tail-flick	hot-plate	locomotion	hypothermia	CPP
2^c	1.2 (1–1.18)	15 (6–19)	4.9 (0.9–46)	9.2 (4–23)	0.35
(<i>S,S</i>)- 4a^c	0.2 (0.06–0.7)	1.0 (0.2–2.2)	0.9 (0.2–5.7)	1.5 (0.15–2.6)	0.1
(<i>R,R</i>)- 4a^c	2.5 (1.2–3.6)	10.3 (5.7–17.1)	IA	IA	NT
(<i>S,S</i>)- 5a	0.036 (0.012–0.1)	IA	IA	IA	NT
(<i>R,R</i>)- 5a	1.26 (0.39–4.1)	3.9 (0.8–19)	IA	IA	NT
(<i>S,S</i>)- 5b	0.02 (0.008–0.03)	IA	4.7 (1.2–19)	IA	NT
(<i>S,S</i>)- 5c	0.006 (0.003–0.01)	IA	2.1 (0.9–4.8)	IA	NT
(<i>S,S</i>)- 5d	0.13 (0.03–0.6)	IA	3.8 (1.2–12)	IA	NT
(<i>S,S</i>)- 5e	0.029 (0.004–0.23)	IA	IA	IA	0.025
(<i>S,S</i>)- 5f	0.056 (0.018–0.17)	IA	IA	IA	0.03
(<i>S,S</i>)- 5g	0.018 (0.009–0.03)	9.6 (1.2–77)	2.7 (0.7–10.5)	2.5 (1.6–3.9)	NT
(<i>S,S</i>)- 5h	0.017 (0.002–0.15)	IA	0.49 (0.03–6.6)	IA	NT

^a Results were expressed as AD₅₀ (mg/kg) ± confidence limits (CL) or % effect at the highest dose tested. Dose–response curves were determined using a minimum of four different doses of test compound, and at least eight mice were used per dose group. IA = AD₅₀ > 20 mg/kg. ^b NT = not tested. ^c Taken from ref 13.

Compound **5d**, which is the *N*-methyl analogue of (*S,S*)-**5a**, has an nAChR profile similar to that of (*S,S*)-**5a**, with similar selectivity for $\alpha 3\beta 4^*$ -nAChR over other subtypes but with slightly higher potency at $\alpha 3\beta 4^*$ -nAChR. The *N*-ethyl and *N*-propyl analogues **5e** and **5f** have IC₅₀ values of 0.79 and 0.98 μ M at the $\alpha 3\beta 4^*$ -nAChR, which makes them 4.2- and 3.4-fold more potent than (*S,S*)-**5a** and about two times more potent than (*R,R*)-**5a** at $\alpha 3\beta 4^*$ -nAChRs. Compounds **5g** and **5h** have $\alpha 3\beta 4^*$ -nAChR profiles similar to that of (*S,S*)-**5a**, although the propyl analogue **5h** has slightly higher potency across all nAChR subtypes.

Behavioral Effects of Analogues. Compound (*S,S*)-**4a** blocks nicotine-induced antinociception in the tail-flick, hot-plate, locomotor depression, and hypothermia measures with AD₅₀ values of 0.2, 1.0, 0.9, and 1.5 mg/kg, respectively (Table 2). None of the analogues was more potent than (*S,S*)-**4a** in the hot-plate and hypothermia tests, and only **5h** with an AD₅₀ of 0.49 mg/kg was more potent than (*S,S*)-**4a** in the locomotor test. However, eight analogues were more potent (AD₅₀ values ranged from 0.006 to 0.13 mg/kg) in the tail-flick test than (*S,S*)-**4a**, with four of the analogues also being substantially more potent than (*S,S*)-**5a**. Compound (*S,S*)-**5a** with an AD₅₀ of 0.036 mg/kg in the tail-flick test is 5.5 times more potent than (*S,S*)-**4a** despite being inactive in the other three tests of acute nicotine action in mice. The arylbromo analogue **5c** is six times more potent in the tail-flick test than (*S,S*)-**5a** and ~33 times more potent than (*S,S*)-**4a** and has an AD₅₀ of 2.1 mg/kg in the locomotor test. The arylfluoro analogue **5b** has slightly lower potency than (*S,S*)-**5c** in the tail-flick and locomotor tasks. Moreover, each of the *N*-substituted and the alkyl extended analogues had higher potency than (*S,S*)-**4a** in the tail-flick assay.

In part because their in vitro potency as antagonists of $\alpha 3\beta 4^*$ -nAChR and as inhibitors of DA and NE uptake were nearly the highest of the analogues tested, **5e** and **5f** were tested in mice for the ability to block nicotine rewarding effects as measured in the CPP test. Both compounds dose-dependently blocked the development of nicotine-induced CPP, and they were 4- and 3-fold more potent in that assay than (*S,S*)-**4a** (Table 2).

DISCUSSION

We have generated the 3,5,5-trimethylmorpholine analogues **5a–5h** of the hydroxybupropion isomer (*S,S*)-**4a** where the

2-hydroxyl group has been replaced with a hydrogen and assessed the abilities of these analogues to affect DA, NE, and 5HT uptake, function of four nAChR subtypes, and the acute effects of nicotine and in CPP, which measures reward-related phenomena. The (*S,S*) analogues of **5a** to **5h** have greater potency than the reference compounds **2** and (*S,S*)-**4a** as inhibitors of DA or NE uptake. All the compounds have higher potency as antagonists of $\alpha 3\beta 4^*$ -nAChR function than (*S,S*)-**4a**, and four of the compounds, **5a**, **5c**, **5e**, and **5f**, are more potent than **2**. A comparison of the effects of aromatic substituents on **5a–5h** shows a rank order potency at $\alpha 3\beta 4^*$ -nAChR of alkyl-bromo > -chloro > -fluoro (**5c** > **5a** > **5b**). *N*-Alkylation of (*S,S*)-**5a** provided the *N*-methyl, *N*-ethyl, and *N*-propyl analogues **5d–5f**. Whereas the *N*-methyl analogue **5d** had about equal potencies at all the in vitro assays tested, the *N*-ethyl and *N*-propyl analogues **5e** and **5f**, respectively, had significantly higher potency for DA and NE uptake inhibition as well as antagonism of the $\alpha 3\beta 4^*$ -nAChR. The carbon-3 extended 3-ethyl and 3-propyl analogues **5g** and **5h**, respectively, both had significantly higher DA and NE uptake inhibition relative to (*S,S*)-**5a**. Analogue **5g** had slightly lower $\alpha 3\beta 4^*$ -nAChR antagonist potency relative to (*S,S*)-**5e**, whereas **5h** had about the same $\alpha 3\beta 4^*$ -nAChR antagonist potency as (*S,S*)-**5a**. With AD₅₀ values of 0.017 to 0.13 mg/kg, all *N*-substituted and carbon-3 extended chain analogues **5d–5h** are potent antagonists of nicotine-induced antinociception in the tail-flick test. With AD₅₀ values of 0.018 and 0.017 mg/kg, the extended chain analogues **5g** and **5h** have the highest potency in the tail-flick test. Importantly, the two analogues selected for further study based in part on in vitro profiling results, *N*-ethyl and *N*-propyl derivatives **5e** and **5f**, with AD₅₀ values of 0.025 and 0.03 mg/kg, respectively, have better potency as antagonists of nicotine-induced CPP than **2** and (*S,S*)-**4a**, which have AD₅₀ values of 0.35 and 0.1 mg/kg, respectively. The antagonist activity of **2** in this assay is consistent with its ability to promote smoking cessation, probably via its hydroxymetabolite.

In our previous studies,^{8,11–13} we succeeded in generating analogues with reasonably higher inhibitory potency than **2** or either of its hydroxymetabolite isomers (*R,R*)-**4a** and (*S,S*)-**4a** in both the in vitro and In Vivo assays used in this study, whether on

the 2, hydroxybupropion, or 3-phenyltropane backbones.^{8,12,13} The current studies show that several 3,5,5-morpholino analogues **5a**–**5h** also have higher potency than 2, (*R,R*)-**4a**, and (*S,S*)-**4a** in the same test.

Interestingly, (*S,S*)-**5a**, which has a hydrogen in place of the 2-hydroxy group in (*S,S*)-**4a**, has a higher potency than (*S,S*)-**4a** at the targets of interest, DAT, NET, and $\alpha 3\beta 4^*$ -nAChR but not at $\alpha 4\beta 2$ -nAChR, a subtype that has been implicated in nicotine dependence. Because DA in the nucleus accumbens undoubtedly plays a role in reinforcement and reward, and NE input from the locus coeruleus can gate activity in dopaminergic nuclei and enhance attention, inhibition of reuptake at either could contribute to nicotine's dependence-related behavioral effects.

Recent genetic studies suggest that $\alpha 3\beta 4^*$ -nAChR subtypes play an important role in nicotine dependence. Indeed, genetic variants in the nAChR $\alpha 3/\beta 3/\alpha 5$ subunit gene cluster are associated with susceptibility to nicotine dependence in humans, perhaps consistent with the presence of $\alpha 3\beta 4^*$ -nAChR at key portions in the extended reward circuit.^{15–17}

Our earlier studies indicated that conversion of 2 to its (*S,S*)-hydroxymetabolite (*S,S*)-**4a** was associated with an increase in compound potency in inhibition of acute nicotine effects to the same degree that the latter compound also displayed an increase in potency as an inhibitor and selectivity for $\alpha 4\beta 2$ -nAChR.⁹ This suggested that efforts to increase potency at $\alpha 4\beta 2$ -nAChR might lead to discovery of better bupropion-related aids to smoking cessation. It was not clear whether the hydroxy moiety itself, the specific atomic topography of the (*S,S*)-hydroxymetabolite, or some combination of both, contributed to the increased behavioral and $\alpha 4\beta 2$ -nAChR potency of the compound relative to 2.

The current studies indicate that the hydroxy moiety could contribute to enhanced selectivity of bupropion-related compounds for $\alpha 4\beta 2$ -nAChR, as its removal from (*S,S*)-**4a** in (*S,S*)-**5a** correlates with a decline in antagonist potency at $\alpha 4\beta 2$ -nAChR. Interestingly, as opposed to the preference of (*R,R*)-**4a** for $\alpha 3\beta 4^*$ -nAChR and of (*S,S*)-**4a** for $\alpha 4\beta 2$ -nAChR, both isomers (*R,R*)- and (*S,S*)-**5a** are slightly selective for $\alpha 3\beta 4^*$ -over $\alpha 4\beta 2$ -nAChR and have indistinguishable antagonist potencies at $\alpha 4\beta 2$ -nAChR, although (*S,S*)-**4a** or -**5a** are both less potent than their (*R,R*)-equivalents at $\alpha 3\beta 4^*$ -nAChR. Moreover, all of the other (*S,S*)-**5** analogues have higher potency at $\alpha 3\beta 4^*$ -than at $\alpha 4\beta 2$ -nAChR.

With regard to activity as monoamine uptake inhibitors, higher potency for (*S,S*) as opposed to (*R,R*)-**4a** and -**5a** is evident at DAT and NET and there is a substantial increase in potency when either isomeric form is changed from the hydroxyl- to the hydrogen form. Moreover, each of the (*S,S*)-**5a** variants has higher DA and NE uptake inhibitory potency except for the *N*-methyl analogue **5d** and the bromo-substituted analogue **5c** acting at the NET. The alkyl extension analogues **5g** and **5h** also have higher potency for SHT uptake inhibition.

It is possible that good activity in DA and/or NE uptake inhibition and slight adjustments in activity at nAChR may be key to developing a compound with desired, increased efficacy as a smoking cessation aid. However, strong activity in either DA or NE uptake inhibition also might be adequate to decrease nicotine dependence measures. In no case is potency at nAChR greater than that for DA or NE uptake inhibition for analogues **5b**–**5h**. Submicromolar IC₅₀ values for inhibition of DA uptake is a characteristic of the most potent inhibitors of nicotine effects in the tail-flick assay. Comparative differences in activity in the tail-flick assay do not match with comparative differences in

inhibitory potency at any single molecular target. The similarities in the abilities of **5e** and **5f** to block nicotine-induced CPP (AD₅₀ = 0.025 and 0.03 mg/kg, respectively) can be reconciled with the similar activities of those agents at DA and NE uptake inhibition and/or $\alpha 3\beta 4^*$ -nAChR antagonism, as their 3–4-fold better activity in nicotine-CPP blockade relative to (*S,S*)-**4a** could be attributed to their ~10-fold higher potency at these molecular targets.

CONCLUSIONS

In summary, replacement of 2-hydroxyl groups in the (*S,S*)-hydroxybupropion (**4a**) with a hydrogen to give (*S,S*)-**5a** resulted in increased potency for inhibition of DA and NE uptake, antagonism of $\alpha 3\beta 4^*$ -nAChR, and increased potency for antagonizing nicotine-induced antinociception in the tail-flick test. The *N*-ethyl and *N*-propyl analogues, **5e** and **5f**, respectively, of (*S,S*)-**5a** were more potent DA and NE uptake inhibitors as well as antagonists of $\alpha 3\beta 4^*$ -nAChRs than (*S,S*)-**4a** and (*S,S*)-**5a**. The aryl fluoro and bromo analogues **5b** and **5c**, respectively, and carbon-3 extended chain analogues **5g** and **5h** all have higher DA uptake inhibition potency than (*S,S*)-**4a** and (*S,S*)-**5a**. All (*S,S*)-**5** analogues are more potent in the tail-flick test than (*S,S*)-**4a**. The *N*-ethyl and *N*-propyl analogues **5e** and **5f**, respectively, which have the highest antagonist potency at $\alpha 3\beta 4^*$ -nAChR as well as high potency for DA and NE uptake inhibition, also had better potency than (*S,S*)-**4a** in the nicotine-CPP test. Thus, 2 and (*S,S*)-**4a** analogues **5a**–**5h**, particularly **5e** and **5f**, represent exciting new lead structures for the development of new pharmacotherapies to treat nicotine addiction (smokers).

EXPERIMENTAL SECTION

Nuclear magnetic resonance (¹H NMR and ¹³C NMR) spectra were recorded on a 300 MHz (Bruker AVANCE 300) unless otherwise noted. Chemical shift data for the proton resonances were reported in parts per million (δ) relative to internal (CH₃)₄Si (δ 0.0). Optical rotations were measured on an AutoPol III polarimeter, purchased from Rudolph Research. Elemental analyses were performed by Atlantic Microlab, Norcross, GA. Purity of compounds (>95%) was established by elemental analyses. Analytical thin-layer chromatography (TLC) was carried out on plates precoated with silica gel GHLF (250 μ M thickness). TLC visualization was accomplished with a UV lamp or in an iodine chamber. All moisture-sensitive reactions were performed under a positive pressure of nitrogen maintained by a direct line from a nitrogen source. Anhydrous solvents were purchased from Aldrich Chemical Co.

(*S,S*)-2-(3'-Chlorophenyl)-3,5,5-trimethylmorpholine [(*S,S*)-5a**] Hemi-D-tartrate.** A solution of (*S,S*)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine-2-ol [(*S,S*)-**4a**] hemi-D-tartrate (990 mg, 3.00 mmol) in 12 mL of 50% aqueous ethanol was cooled at 0 °C and treated with NaBH₄ (450 mg, 12 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched at 0 °C by the slow addition of 4.5 mL of concentrated HCl. The clear solution was basified with saturated aqueous solution of NaCO₃ and extracted twice with ethyl acetate. The combined extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure, affording 470 mg of crude mixture of diols. The crude reaction mixture was dissolved in 5 mL of CH₂Cl₂, cooled to 0 °C, and treated dropwise with 4 mL of concentrated H₂SO₄. The mixture was stirred overnight with warming to room temperature. The reaction mixture was added to crushed ice, basified with aqueous solution of sodium carbonate, and extracted with ether (twice). The combined extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting oil was purified by

flash chromatography using CH₂Cl₂–methanol (10:1) plus 1% ammonium hydroxide as the eluent to afford 300 mg (42%) of (S,S)-**5a**. ¹H NMR (CDCl₃) δ 7.38–7.35 (m, 1H), 7.28–7.20 (m, 3H), 3.78 (d, 1H, *J* = 9.3 Hz), 3.68 (d, 1H, *J* = 11.0 Hz), 3.34 (d, 1H, *J* = 11.0 Hz), 3.12–3.01 (m, 1H), 1.39 (s, 3H), 1.07 (s, 3H), 0.82 (d, 3H, *J* = 6.3 Hz). ¹³C NMR (CDCl₃) δ 142.2, 134.5, 129.8, 128.24, 127.7, 125.9, 86.2, 77.4, 51.1, 49.9, 27.4, 23.6, 18.5.

A sample of the (S,S)-**5a** was converted to the hemi-D-tartrate salt: mp 209–210 °C; [α]_D²⁰ +7.6° (c 0.7, CH₃OH). ¹H NMR (methanol-*d*₄) δ 7.48–7.45 (m, 1H), 7.41–7.35 (m, 3H), 4.37 (s, 1H), 4.29 (d, 1H, *J* = 10.0 Hz), 3.76 (dd, 2H, *J* = 30.5, *J* = 12.3 Hz), 3.58–3.50 (m, 1H), 1.58 (s, 3H), 1.35 (s, 3H), 1.04 (d, 3H, *J* = 6.5 Hz). ¹³C NMR (methanol-*d*₄) δ 177.6, 140.8, 135.6, 131.3, 130.2, 128.7, 127.3, 83.5, 74.9, 74.4, 55.1, 52.2, 23.8, 21.2, 15.4. MS (ESI) *m/z* 240.2 [(M – tartrate)⁺; M = C₁₃H₁₈ClNO · 0.5C₄H₆O₆]. Anal. (C₁₅H₂₁ClNO₄ · 0.25 H₂O) C, H, N.

(R,R)-2-(3'-Chlorophenyl)-3,5,5-trimethylmorpholine [(R,R)-5a**] Hemi-L-tartrate.** A procedure similar to the one reported for (S,S)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (S,S)-**5a** was used. A sample of (R,R)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine-2-ol [(R,R)-**4a**] hemi-D-tartrate (660 mg, 2.00 mmol) in 8 mL of 50% aqueous ethanol was treated with NaBH₄ (300 mg, 8.00 mmol) to give 540 mg of a crude mixture of diols **6a**. A solution of the crude sample in CH₂Cl₂ (6 mL) was treated with 3 mL of concentrated H₂SO₄ to afford 364 mg (76% yield) of (2R,3R)-**5a**. ¹H NMR (CDCl₃) δ 7.38–7.36 (m, 1H), 7.29–7.20 (m, 3H), 3.77 (d, 1H, *J* = 9.3 Hz), 3.69 (d, 1H, *J* = 9.0 Hz), 3.34 (d, 1H, *J* = 12.0 Hz), 3.11–3.02 (m, 1H), 1.43 (s, 3H), 1.07 (s, 3H), 0.81 (d, 3H, *J* = 6.0 Hz). ¹³C NMR (CDCl₃) δ 142.2, 134.4, 129.7, 128.3, 127.7, 126.0, 86.2, 77.5, 51.1, 49.7, 27.4, 23.6, 18.5.

A sample of the (R,R)-**5a** was converted to the hemi-L-tartrate salt: mp 210–211 °C; [α]_D²⁰ –10.2° (c 0.5, CH₃OH). ¹H NMR (methanol-*d*₄) δ 7.47–7.43 (m, 1H), 7.40–7.31 (m, 3H), 4.35 (s, 1H), 4.26 (d, 1H, *J* = 10.2 Hz), 3.74 (dd, 2H, *J* = 32.1, *J* = 12.2 Hz), 3.57–3.41 (m, 1H), 1.56 (s, 3H), 1.32 (s, 3H), 1.02 (d, 3H, *J* = 6.6 Hz). ¹³C NMR (methanol-*d*₄) δ 178.1, 141.2, 135.6, 131.2, 130.1, 128.7, 127.3, 83.8, 75.2, 74.7, 54.6, 52.2, 24.1, 21.4, 15.6. MS (ESI) *m/z* 240.1 [(M – tartrate)⁺; M = C₁₃H₁₈ClNO · 0.5C₄H₆O₆]. Anal. (C₁₅H₂₁ClNO₄) C, H, N.

(S,S)-2-(3'-Fluorophenyl)-3,5,5-trimethylmorpholine (5b**) Hemi-D-tartrate.** A solution of (S,S)-2-(3'-fluorophenyl)-3,5,5-trimethylmorpholine (**4b**) hemi-D-tartrate (220 mg, 0.700 mmol) in 4 mL of EtOH/H₂O (1:1) was cooled at 0 °C and treated with NaBH₄ (106 mg, 2.80 mmol). The reaction mixture was stirred at room temperature overnight. After cooling the reaction mixture at 0 °C, 1 mL of HCl 1.6 M solution in EtOH was added slowly to the reaction vessel and the mixture was allowed to warm to room temperature. Ether and NaHCO₃ saturated aqueous solution were added to the reaction vessel, and the organic layer was separated. The aqueous phase was extracted with ether (three times). The combined organic extracts were washed (water, brine), dried (Na₂SO₄), and concentrated to give **6b** as a white solid 124 mg (74% yield). ¹H NMR (CDCl₃) δ 7.33–7.27 (m, 1H), 7.11–7.04 (m, 2H), 6.98–6.89 (m, 1H), 4.58 (d, 1H, *J* = 4.0 Hz), 3.37 (dd, 2H, *J* = 26.2, *J* = 10.7 Hz), 3.13–3.02 (m, 1H), 1.12 (s, 3H), 1.10 (s, 3H), 0.85 (d, 3H, *J* = 6.7 Hz). ¹³C NMR (CDCl₃) δ 129.4 (d), 121.9 (d), 114.1, 113.8, 113.5, 113.2, 75.5, 69.7, 54.3, 51.5, 25.2, 24.6, 18.2. MS (ESI) *m/z* 242.3 [(M + H)⁺, M = C₁₃H₁₈FNO₂].

A solution of crude diol **6b** (110 mg, 0.455 mmol) in CH₂Cl₂ (2 mL) was cooled at 0 °C and treated with 1 mL of concentrated H₂SO₄. The reaction mixture was stirred at room temperature overnight and then poured into a flask with crushed ice. The mixture was neutralized with NaHCO₃ saturated aqueous solution, followed by extraction with ether (three times). The organic layers were separated, combined, washed (water, brine), separated, dried (Na₂SO₄), and concentrated to a white solid 58 mg (57% yield). ¹H NMR (CDCl₃) δ 7.34–7.28 (m, 1H), 7.14–6.97 (m, 3H), 3.78 (d, 1H, *J* = 9.2 Hz), 3.70 (d, 1H, *J* = 11.0 Hz), 3.34 (d, 1H, *J* = 11.0 Hz), 3.10–3.01 (m, 1H), 1.39 (s, 3H), 1.08 (s, 3H),

0.82 (d, 3H, *J* = 6.3 Hz). ¹³C NMR (CDCl₃) δ 164.6, 142.7, 129.9 (d), 123.3 (d), 115.1 (d), 114.3 (d), 86.2, 77.4, 51.1, 49.2, 27.4, 23.5, 18.5. MS (ESI) *m/z* 222.4 [(M – H)⁺, M = C₁₃H₁₈FNO].

A sample of free base (54 mg, 0.24 mmol) in 2 mL of ether was treated with a solution of D-tartaric acid (18 mg, 0.12 mmol) in MeOH (1 mL) to give 61 mg (85% yield) of **5b**·tartrate as a white solid: mp 167–168 °C; [α]_D²⁰ +9.1° (c 0.9, CH₃OH). ¹H NMR (methanol-*d*₄) δ 7.45–7.36 (m, 1H), 7.25–7.09 (m, 3H), 4.36 (s, 1H), 4.28 (d, 1H, *J* = 10.0 Hz), 3.74 (dd, 2H, *J* = 30.4, *J* = 12.0 Hz), 3.52–3.43 (m, 1H), 1.56 (s, 3H), 1.32 (s, 3H), 1.02 (d, 3H, *J* = 6.5 Hz). ¹³C NMR (CD₃OD) δ 165.9, 141.6, 131.5 (d), 124.7 (d), 116.7 (d), 115.4 (d), 83.8, 75.2, 74.7, 54.7, 52.2, 24.1, 21.4, 15.6. MS (ESI) *m/z* 224.3 [(M – tartrate)⁺, M = C₁₃H₁₈FNO · 0.5C₄H₆O₆]. Anal. (C₁₅H₂₁FNO₄ · 0.25H₂O) C, H, N.

(S,S)-2-(3'-Bromophenyl)-3,5,5-trimethylmorpholine (5c**) Hemi-D-tartrate.** A procedure similar to the one reported for (S,S)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (S,S)-**5a** was used to synthesize **5c**. A solution of (S,S)-2-(3'-bromophenyl)-3,5,5-trimethylmorpholine-2-ol (**4c**) D-tartrate (265 mg, 0.710 mmol) in 4 mL of 50% aqueous ethanol was treated with NaBH₄ (107 mg, 2.83 mmol) to give 215 mg of a crude mixture of diols. The crude reaction mixture was dissolved in CH₂Cl₂ (4 mL) and treated with 2 mL of concentrated H₂SO₄ to afford 150 mg (74%) of (S,S)-**5c**. ¹H NMR (CDCl₃) δ 7.53–7.50 (m, 1H), 7.44–7.40 (m, 1H), 7.25–7.17 (m, 2H), 3.75 (d, 1H, *J* = 9.3 Hz), 3.69 (d, 1H, *J* = 11.1 Hz), 3.33 (d, 1H, *J* = 11.4 Hz), 3.11–3.01 (m, 1H), 1.39 (s, 3H), 1.07 (s, 3H), 0.81 (d, 3H, *J* = 6.3 Hz). ¹³C NMR (CDCl₃) δ 142.5, 131.3, 130.5, 130.0, 126.4, 122.7, 86.1, 77.4, 50.8, 49.8, 27.4, 23.6, 18.6.

A sample of the free base was converted to the title compound: mp 212–213 °C; [α]_D²⁰ +7.6° (c 0.63, CH₃OH). ¹H NMR (methanol-*d*₄) δ 7.59–7.51 (m, 1H), 7.39–7.25 (m, 3H), 4.35 (s, 1H), 4.26 (d, 1H, *J* = 10.0 Hz), 3.79 (d, 1H, *J* = 12.2 Hz), 3.68 (d, 1H, *J* = 12.2 Hz), 3.51–3.45 (m, 1H), 1.56 (s, 3H), 1.32 (s, 3H), 1.02 (d, 3H, *J* = 6.6 Hz). ¹³C NMR (methanol-*d*₄) δ 177.8, 141.5, 133.0, 131.5 (d), 127.7, 123.5, 84.0, 75.4, 74.6, 54.3, 52.2, 24.3, 21.5, 15.8. MS (ESI) *m/z* 284.7 [(M – tartrate)⁺; M = C₁₃H₁₈BrNO · 0.5C₄H₆O₆]. Anal. (C₁₅H₂₁BrNO₄) C, H, N.

(S,S)-2-(3'-Chlorophenyl)-3,4,5,5-tetramethylmorpholine (5d**) Hydrochloride.** A sample of (S,S)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (**5a**) (60 mg, 0.25 mmol) and potassium carbonate (104 mg, 0.750 mmol) in 1.5 mL of DMF were charged in a sealed flask apparatus and treated with CH₃I (19 μL, 0.30 mmol). The reaction vessel was sealed and stirred overnight at 70 °C. The reaction mixture was cooled to room temperature, diluted with water, and extracted twice with ether. The combined extracts were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The resulting oil was purified by column chromatography using CH₂Cl₂–methanol (30:1) as eluent, afforded 45 mg (71%) of **5d**. ¹H NMR (CDCl₃) δ 7.38–7.36 (m, 1H), 7.25–7.21 (m, 3H), 4.04 (d, 1H, *J* = 9.6 Hz), 3.54 (q, 1H, *J* = 11.1 Hz), 2.62–2.53 (m, 1H), 2.25 (s, 3H), 1.19 (s, 3H), 1.07 (s, 3H), 0.83 (d, 3H, *J* = 6.3 Hz). ¹³C NMR (CDCl₃) δ 142.6, 134.3, 129.5, 128.29, 128.04, 126.4, 85.5, 78.1, 57.3, 34.2, 25.0, 15.7, 14.1.

A sample of **5d** was converted to the hydrochloride salt: mp 212–213 °C; [α]_D²⁰ +51.9° (c 0.75, CH₃OH); MS (ESI) *m/z* 254.6 [(M – HCl)⁺; M = C₁₄H₂₀ClNO · HCl]. Anal. (C₁₄H₂₁Cl₂NO) C, H, N.

(S,S)-2-(3'-Chlorophenyl)-4-ethyl-3,5,5-trimethylmorpholine (5e**) Di-*p*-toluoyl-L-tartrate.** A sample of (S,S)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (**5a**) (320 mg, 1.33 mmol) was dissolved in 5 mL of dichloroethane and treated with NaBH(OAc)₃ (117 mg, 2.66 mmol) and an excess amount of acetaldehyde. The reaction mixture was stirred at room temperature overnight. The reaction was quenched with aqueous solution of sodium carbonate and extracted with ether. The combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The crude product was purified by column chromatography on silica gel using cyclohexane–ethyl acetate (5:1) with 1% NH₄OH as the eluent to give 150 mg (42%) of

(*S,S*)-**5e** as colorless oil. ^1H NMR (CDCl_3) δ 7.36 (s, 1H), 7.25 (m, 3H), 4.00 (d, 1H), 3.50 (dd, 2H), 2.72 (m, 2H), 2.27 (m, 1H), 1.22 (s, 3H), 1.05 (t, 3H), 1.04 (s, 3H), 0.82 (d, 3H). ^{13}C NMR (CDCl_3) δ 142.9, 134.5, 129.8, 128.6, 128.4, 126.7, 86.2, 78.5, 57.5, 54.6, 42.6, 25.4, 19.3, 17.1, 16.4. m/z 268.0 $[(\text{M} + \text{H})^+]$. $\text{M} = \text{C}_{15}\text{H}_{22}\text{ClNO}$.

A sample of the **5e** was converted to the di-*p*-toluoyl-L-tartrate salt: mp 165–166 °C; $[\alpha]_{\text{D}}^{20} -81.4^\circ$ (c 0.56, CH_3OH). Anal. ($\text{C}_{35}\text{H}_{40}\text{ClNO}_9$) C, H, N.

(*S,S*)-2-(3'-Chlorophenyl)-3,5,5-trimethyl-4-propylmorpholine (**5f**) Di-*p*-toluoyl-L-tartrate. Compound **5f** was prepared in the same fashion as **5e**, using (*S,S*)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (**5a**) (320 mg, 1.33 mmol) in 5 mL of dichloroethane and was treated with $\text{NaBH}(\text{OAc})_3$ (790 mg, 3.74 mmol) and an excess amount of propionaldehyde to afford 220 mg (75%) of **5f**. ^1H NMR (CDCl_3) δ 7.36 (s, 1H), 7.23 (m, 3H), 4.00 (d, 1H), 3.50 (dd, 2H), 2.72 (m, 1H), 2.55 (m, 1H), 2.10 (m, 1H), 1.45 (m, 2H), 1.22 (s, 3H), 1.02 (s, 3H), 0.82 (t, 3H), 0.79 (d, 3H). ^{13}C NMR (CDCl_3) δ 142.9, 134.5, 129.8, 128.5, 128.4, 126.7, 86.1, 78.3, 57.7, 54.4, 51.2, 27.2, 25.5, 17.2, 16.1, 11.9. m/z 282.6 $[(\text{M} + \text{H})^+]$, $\text{M} = \text{C}_{16}\text{H}_{24}\text{ClNO}$.

A sample of the **5f** was converted to the di-*p*-toluoyl-L-tartrate salt: mp 144–145 °C; $[\alpha]_{\text{D}}^{20} -67.2^\circ$ (c 0.6, CH_3OH). Anal. ($\text{C}_{36}\text{H}_{42}\text{ClNO}_9$) C, H, N.

(*S,S*)-2-(3'-Chlorophenyl)-3-ethyl-5,5-dimethylmorpholine (**5g**) Hemi-D-tartrate. A procedure similar to the one described for (*S,S*)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (*S,S*)-**5a** was used to synthesize (*S,S*)-**5g**. A sample of (*S,S*)-2-(3'-chlorophenyl)-3-ethyl-5,5-dimethylmorpholine-2-ol-D-tartrate (**4g**) (100 mg, 0.230 mmol) in 2 mL of 50% aqueous ethanol was treated with NaBH_4 (45 mg, 1.2 mmol) to give 74 mg of a crude mixture of diols **6g**. A solution of the crude sample in 2 mL of CH_2Cl_2 was treated with 1 mL of concentrated sulfuric acid to afford 54 mg (98%) of (*S,S*)-**5g**. The free base was converted to its hemi-D-tartrate salt by dissolving the free base on methanol and adding 16.9 mg (0.5 equivalent) of D-tartaric acid dissolved in methanol: mp 203–204 °C; $[\alpha]_{\text{D}}^{20} -4.2^\circ$ (c 0.5, CH_3OH). ^1H NMR (CD_3OD) δ 7.47 (s, 1H), 7.39 (s, 3H), 4.36 (s, 1H), 4.27 (d, 1H), 3.76 (d, 1H), 3.66 (d, 1H), 1.56 (s, 3H), 1.40 (m, 2H), 1.32 (s, 3H), 0.75 (t, 3H). ^{13}C NMR (CD_3OD) δ 178.2, 141.8, 136.0, 131.7, 130.5, 129.3, 127.9, 83.7, 75.7, 74.9, 58.2, 55.0, 24.5, 21.9, 10.7. m/z 254.0 $[(\text{M} - \text{tartrate})^+]$. $\text{M} = \text{C}_{16}\text{H}_{23}\text{ClNO}_4$. Anal. ($\text{C}_{16}\text{H}_{23}\text{ClNO}_4 \cdot 0.25\text{H}_2\text{O}$) C, H, N.

(*S,S*)-2-(3'-Chlorophenyl)-5,5-dimethyl-3-propylmorpholine (**5h**) Hemi-D-tartrate. A procedure similar to the one reported for (*S,S*)-2-(3'-chlorophenyl)-3,5,5-trimethylmorpholine (*S,S*)-**5a** was used to synthesize **5h**. Treatment of (*S,S*)-2-(3'-chlorophenyl)-5,5-dimethyl-3-propylmorpholine-2-ol (**4h**) hemi-D-tartrate (360 mg, 1.00 mmol) in 6 mL of 50% aqueous ethanol with NaBH_4 (151 mg, 4.00 mmol) afforded 295 mg of a crude mixture of diols. The crude sample was dissolved in 4 mL of CH_2Cl_2 and treated with 2 mL of concentrated H_2SO_4 to give 250 mg (98%) of **5h**. Compound **5h** was converted to its hemi-D-tartrate salt: mp 232–233 °C; $[\alpha]_{\text{D}}^{20} -19.0^\circ$ (c 1.1, CH_3OH). ^1H NMR (CD_3OD) δ 7.47 (s, 1H), 7.40–7.36 (m, 3H), 4.36 (s, 1H), 4.30 (d, 1H), 3.78–3.66 (m, 2H), 3.37–3.29 (m, 2H), 1.57 (s, 3H), 1.33 (s, 3H), 1.26–1.40 (m, 1H), 0.94–0.92 (m, 1H), 0.74 (t, 3H). ^{13}C NMR (CD_3OD) δ 178.4, 141.8, 136.0, 131.7, 130.5, 129.3, 83.7, 75.5, 75.1, 56.6, 55.1, 33.6, 24.4, 21.8, 20.1, 14.4; m/z 268.0 $[(\text{M} - \text{tartrate})^+]$. $\text{M} = \text{C}_{17}\text{H}_{25}\text{ClNO}_4$. Anal. ($\text{C}_{17}\text{H}_{25}\text{ClNO}_4$) C, H, N.

Cell Lines and Culture. Human embryonic kidney (HEK-293) cells stably expressing human DAT, NET, or SERT were maintained as previously described.¹⁸ Several human cell lines that naturally or heterologously express specific, functional, and human nAChR subtypes also were used as described earlier.^{8,12}

Transporter Assays. The abilities of compounds to inhibit uptake of [^3H]DA, [^3H]5HT, or [^3H]NE by the respective, human transporters were evaluated using the appropriate HEK-293 cell line as previously reported.¹⁸

nAChR Functional Assays.⁸⁶ Rubidium ion efflux assays were used as previously described^{8,12} to characterize functional effects of analogues.

Behavioral Assays. All animal experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and Institutional Animal Care and Use Committee guidelines. Male Institute of Cancer Research (ICR) mice (weighing 20–25 g) obtained from Harlan (Indianapolis, IN) were used to test effects of analogues on acute actions of nicotine (tail-flick, hot-plate, locomotor, and body temperature studies) as previously described.^{8,12} Conditioned place preference (CPP) assays also were conducted as specified earlier respectively) or 3-phenyltropanes-related compounds.^{8,11}

■ ASSOCIATED CONTENT

S Supporting Information. Elemental analysis data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Phone: 1.919.541.6679. Fax: 1.919.541.8868. E-mail: fic@rti.org.

■ ACKNOWLEDGMENT

This work was supported by National Institutes of Health National Cooperative Drug Discovery Group grant U19 DA019377.

■ ABBREVIATIONS USED

NRT, nicotine replacement therapy; DA, dopamine; 5HT, serotonin; NE, norepinephrine; HEK, human embryonic kidney; DAT, dopamine transporter; SERT, serotonin transporter; NET, norepinephrine transporter; nAChR, nicotine acetylcholine receptor(s); VTA, ventral tegmental area; MPE, maximum possible effect; CPP, conditioned place preference

■ REFERENCES

- (1) Benowitz, N. L. Nicotine addiction. *Prim. Care* **1999**, 26, 611–631.
- (2) Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. *Clin. Pharmacol. Ther.* **2008**, 83, 531–541.
- (3) Hughes, J. R.; Higgins, S. T.; Bickel, W. K. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. *Addiction* **1994**, 89, 1461–1470.
- (4) Tutka, P.; Mosiewicz, J.; Wielosz, M. Pharmacokinetics and metabolism of nicotine. *Pharmacol. Rep.* **2005**, 57, 143–153.
- (5) West, R.; McNeill, A.; Raw, M.; Health Education Authority Smoking cessation guidelines for health professionals: an update. *Thorax* **2000**, 55, 987–999.
- (6) Tutka, P. Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. *Expert Opin. Invest. Drugs* **2008**, 17, 1473–1485.
- (7) Rollema, H.; Coe, J. W.; Chambers, L. K.; Hurst, R. S.; Stahl, S. M.; Williams, K. E. Rationale, pharmacology and clinical efficacy of partial agonists of $\alpha 4\beta 2$ nACh receptors for smoking cessation. *Trends Pharmacol. Sci.* **2007**, 28, 316–325.
- (8) Carroll, F. I.; Blough, B. E.; Mascarella, S. W.; Navarro, H. A.; Eaton, J. B.; Lukas, R. J.; Damaj, M. I. Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking Cessation. *J. Med. Chem.* **2010**, 53, 2204–2214.

- (9) Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. *Mol. Pharmacol.* **2004**, *66*, 675–682.
- (10) Slemmer, J. E.; Martin, B. R.; Damaj, M. I. Bupropion is a nicotinic antagonist. *J. Pharmacol. Exp. Ther.* **2000**, *295*, 321–327.
- (11) Damaj, M. I.; Grabus, S. D.; Navarro, H. A.; Vann, R. E.; Warner, J. A.; King, L. S.; Wiley, J. L.; Blough, B. E.; Lukas, R. J.; Carroll, F. I. Effects of hydroxymetabolites of bupropion on nicotine dependence behavior in mice. *J. Pharmacol. Exp. Ther.* **2010**, *334*, 1087–1095.
- (12) Lukas, R. J.; Muresan, A. Z.; Damaj, M. I.; Blough, B. E.; Huang, X.; Navarro, H. A.; Mascarella, S. W.; Eaton, J. B.; Marxer-Miller, S. K.; Carroll, F. I. Synthesis and Characterization of in Vitro and In Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation. *J. Med. Chem.* **2010**, *53*, 4731–4748.
- (13) Carroll, F. I.; Blough, B. E.; Mascarella, S. W.; Navarro, H. A.; Eaton, J. B.; Lukas, R. J.; Damaj, M. I. Nicotinic Acetylcholine Receptor Efficacy and Pharmacological Properties of 3-(Substituted phenyl)-2 β -substituted Tropanes. *J. Med. Chem.* **2010**, *53*, 8345–8353.
- (14) Clarke, F. H. *cis*- and *trans*-3-Methyl-2-phenylmorpholine. *J. Org. Chem.* **1962**, *27*, 3251–3253.
- (15) Bierut, L. J.; Stitzel, J. A.; Wang, J. C.; Hinrichs, A. L.; Gruzca, R. A.; Xuei, X.; Saccone, N. L.; Saccone, S. F.; Bertelsen, S.; Fox, L.; Horton, W. J.; Breslau, N.; Budde, J.; Cloninger, C. R.; Dick, D. M.; Foroud, T.; Hatsukami, D.; Hesselbrock, V.; Johnson, E. O.; Kramer, J.; Kuperman, S.; Madden, P. A.; Mayo, K.; Nurnberger, J., Jr.; Pomerleau, O.; Porjesz, B.; Reyes, O.; Schuckit, M.; Swan, G.; Tischfield, J. A.; Edenberg, H. J.; Rice, J. P.; Goate, A. M. Variants in nicotinic receptors and risk for nicotine dependence. *Am. J. Psychiatry* **2008**, *165*, 1163–1171.
- (16) Saccone, S. F.; Hinrichs, A. L.; Saccone, N. L.; Chase, G. A.; Konvicka, K.; Madden, P. A.; Breslau, N.; Johnson, E. O.; Hatsukami, D.; Pomerleau, O.; Swan, G. E.; Goate, A. M.; Rutter, J.; Bertelsen, S.; Fox, L.; Fugman, D.; Martin, N. G.; Montgomery, G. W.; Wang, J. C.; Ballinger, D. G.; Rice, J. P.; Bierut, L. J. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. *Hum. Mol. Genet.* **2007**, *16*, 36–49.
- (17) Whitten, L. Studies link family of genes to nicotine addiction. *NIDA Notes* **2009**, *22*, 10–14.
- (18) Eshleman, A. J.; Carmolli, M.; Cumbay, M.; Martens, C. R.; Neve, K. A.; Janowsky, A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. *J. Pharmacol. Exp. Ther.* **1999**, *289*, 877–885.